B+
Bull case
25%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
MNPR
Monopar TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Phase 3 FoCus trial met its primary copper-mobilization endpoint, and the rolling NDA plus launch preparations give ALXN1840 a tangible regulatory path. The June cash position supports planned operations through at least December 2027, according to the company.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -5.6.
What can break
Approval would not ensure reimbursement, competitive pricing or patient uptake. Company release
Momentum
11
Value
41
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $85.00 · Bull $125.00 · Bear $42.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $129.91
Why
Momentum11 · Δ7d +5.9
Value41 · Δ7d -0.0
Sentiment75 · Δ7d -5.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -5.6.
Contradictions & invalidation
- • Approval would not ensure reimbursement, competitive pricing or patient uptake. Company release
- • FDA may decline to accept the completed NDA, request additional work or deny approval; rolling submission is not filing acceptance. Company release
- • NDA completion, filing acceptance, approval and commercial uptake are separate hurdles.
Catalyst clock
2026-10-05
ALXN1840 AASLD abstracts and presentations
Lead driver: Sentiment · See AI snapshot
Momentum
11
8% active weight
Current posture
7d trendFlat
Δ7d
+5.9
Δ21d
-4.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
75
45% active weight
Current posture
7d trendSoftening
Δ7d
-5.6
Δ21d
+1.6
Why this grade
Composite grade C. Momentum 10.8 / Value 40.6 / Sentiment 75.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$85.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$474.22M
Beta
1.54
Shares Out
6.71M
P/E (TTM) · Derived
-38.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-44.60
Rev YoY
-
EPS YoY
+77.4%
Gross Margin
-
Op Margin
-
Net Debt
-$140.24M
Current Ratio
33.56
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data